Knowledge is key
By combining our specialized approaches of phage display and single B cell screening technologies with evolutive humanization, we engineer custom-fit immunotherapeutic agents.
Our discovery platform is accessible to biotech and pharma partners. Immune Biosolutions’ platform allows access to highly conserved mammalian lineage targets, opening a potential for innovative therapeutics. It generates antibodies of great diversity, high binding affinity and novel paratopes.
The first of many successes
The company also has a biomanufacturing capacity to produce antibodies and other protein compounds that previously allowed Immune Biosolutions to successfully enter an internal program into clinical trials. This biomanufacturing capacity is also available for partners in a fee-for-service formula.
The company is developing an internal pipeline of several discovery programs for different cancer and Infectious diseases indications.
The experts
in the field
Management team
Luc Paquet, Ph.D.
Chief Executive Officer
Bruno Maranda, M.D.
Chief Medical Officer
Maxime Cloutier, CPA Auditor
Director of Finance
Simon Gaudreau, Ph.D.
Director of Innovation
Co-Founder
Djordje Grbic, Ph.D.
Director of Manufacturing
Jean-François Larrivée, B.Sc.
Director of Nutraceutical Development
Co-Founder
Annie Leroux, B.Sc.
Director of Laboratory Operations
Alexandre Fugere, M.Sc.
Assistant Director of Business Development
Melody Loubat, CRHA
Assistant Director of Human Resources and Administration
Board members
Louise Proulx Ph.D., ICD.D
Executive and Pharmaceutical Consultant, Chair of the Board of Directors
Nicholas Franco
Former C-Suite Executive
Simon Gaudreau, Ph.D.
Director of Innovation
Co-Founder
Yves-Éric Laliberté
Ing. technology entrepreneur and investor, Director of the Board of Directors of Immune Biosolutions
Jean-François Larrivée, B.Sc..
Director of Nutraceutical Development
Co-Founder
Dr. Bruno Maranda, MD, M.Sc, FRCPC, FCCMG
Associate Professor at the University of Sherbrooke and Entrepreneur, Director of the Board of Directors
Inès Holzbaur, Ph.D.
Founder and Managing Partner
Observers
Sylvain Chartier
B.Sc., Ing, MBA, IAS.A.
Luc Tanguay
M.Sc. Finance, CFA
Frédéric Leduc
CSO, EVAH Corp
Scientific Advisory Board members
Andrés Finzi, Ph.D.
Associate professor, Department of Microbiology, Infectiology and Immunology, Université de Montréal. Chairholder Canada Research Chair on Retroviral Entry
Harald Kolmar, Ph.D.
Head of Department of Biochemistry Dean of the Faculty of Chemistry, Professor for Biochemistry, Darmstadt Technical University, Germany
Jean-Marie Leclerc, M.D.
Physician, Hematology-Oncology, HSJ (1985-2021), Chief Scientific Officer at Novartis Canada (2002-2012)
Frédéric Levy, Ph.D.
Executive Director, Head of Search & Evaluation and Scientific Innovation, Debiopharm Sa, Lausanne, Switzerland
